Dr. Patt is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
6204 Balcones Dr
Austin, TX 78731Phone+1 512-427-9400Fax+1 512-342-2723
Education & Training
University of Texas Health Science Center at HoustonFellowship, Hematology and Medical Oncology, 2003 - 2006
Baylor College of MedicineResidency, Internal Medicine/Pediatrics, 1999 - 2003- Baylor College of MedicineClass of 1999
Certifications & Licensure
MI State Medical License 2022 - 2025
TX State Medical License 2003 - 2025
NH State Medical License 2022 - 2024
NE State Medical License 2022 - 2024
ND State Medical License 2022 - 2024
MT State Medical License 2022 - 2024
ME State Medical License 2022 - 2024- American Board of Internal Medicine Medical Oncology
- American Board of Preventive Medicine Clinical Informatics
- Join now to see all
Clinical Trials
- A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread Start of enrollment: 2014 Jun 10
- A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer Start of enrollment: 2014 Jul 22
- Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC) Start of enrollment: 2017 Feb 02
Publications & Presentations
PubMed
- 75 citationsRecommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Clinical Pr...Naren Ramakrishna, Sarah Temin, Sarat Chandarlapaty, Jennie R. Crews, Nancy E. Davidson
Journal of Clinical Oncology. 2018-06-25 - 10 citationsOverall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phas...Frankie A Holmes, Beverly Moy, Suzette Delaloge, Stephen K L Chia, Bent Ejlertsen
European Journal of Cancer. 2023-05-01 - 129 citationsFinal Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial.Arlene Chan, Beverly Moy, Janine Mansi, Bent Ejlertsen, Frankie A. Holmes
Clinical Breast Cancer. 2021-02-01
Lectures
- Operationalizing a Risk Model in Clinical Practice: A Community Oncology PerspectiveASCO Annual Meeting 2019 - Chicago, IL - 6/3/2019
- Understanding Utilization Management-Policy Background: Forms of Utilization Management From a Clinician Perspective.2018 ASCO Annual Meeting - Chicago, Illinois - 06/1/2018
Authored Content
- Using ePROs to Improve Symptom Management and Provide Value-Based CareMarch 2021
Press Mentions
Oncology Leaders Warn Looming Legislation Will Worsen Drug Pricing ProblemSeptember 16th, 2024- What Oncologists Really Think About How Their Peers Look and ActSeptember 9th, 2024
- 17 Books Oncologists Should Read This Summer, According to Their PeersJuly 10th, 2024
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
